← Leaderboards
Julia E Maxson
Oregon Health & Science University
$5,322,132
Attributed
$5,322,132
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $951K · FY2014–25$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$5,322,132 · 5
By mechanism
R01$4,412,951 · 2
R00$732,945 · 1
K99$161,236 · 1
R13$15,000 · 1
Top collaborators
No co-investigators on record.
Most similar at Oregon Health & Science University
Same institution · by research overlap
- Jeffrey Wallace Tyner$13,872,769
- Haijiao Zhang$1,696,427
- Zachary David Urdang$188,874
- Sarah Ann Carratt$195,098
- Theodore Paul Braun$2,536,053
Others in their field
Top investigators on “Bone Marrow”
- Charles A Coltman · Southwest Oncology Group$141,983,231
- Mary M Horowitz · Medical College Of Wisconsin$136,789,389
- David Heimbrook · Leidos Biomedical Research, Inc.$56,049,457
- Richard L Schilsky · University Of Chicago$50,043,295
- Robert L Comis · Frontier Sci &Technology Rsch Fdn, Inc$48,148,202
- J. Mark Cline · Wake Forest University$31,844,583
Research focus
Bone MarrowMutationSignal TransductionMolecularMutantNeutrophilComplexGranulocyte Colony-Stimulating Factor ReceptorsMyelogenousEpigenetic ProcessImpairmentGenetic TranscriptionFunctional DisorderMyeloid CellsHematologic NeoplasmsPhenotypeBiologyProgramsKnock-DownGenesBiogenesisEventEvolutionCells
Grant awards (18)
Role of ASXL1 in normal and abnormal granulopoiesis.$479,787
R01 · FY2025 · HL · contact PI
Mechanisms of differentiation blockade in CSF3R-mutant AML$379,538
R01 · FY2025 · CA · contact PI
Mechanisms of differentiation blockade in CSF3R-mutant AML$76,690
R01 · FY2025 · CA · contact PI
Hematologic Malignancies$15,000
R13 · FY2025 · CA · contact PI
Role of ASXL1 in normal and abnormal granulopoiesis.$470,191
R01 · FY2024 · HL · contact PI
Mechanisms of differentiation blockade in CSF3R-mutant AML$360,561
R01 · FY2024 · CA · contact PI
Aberrant STAT Function in CEBPA-mutant Acute Myeloid Leukemia$75,799
R01 · FY2024 · CA · contact PI
Role of ASXL1 in normal and abnormal granulopoiesis.$479,787
R01 · FY2023 · HL · contact PI
Mechanisms of differentiation blockade in CSF3R-mutant AML$371,948
R01 · FY2023 · CA · contact PI
Role of ASXL1 in normal and abnormal granulopoiesis.$479,787
R01 · FY2022 · HL · contact PI
Mechanisms of differentiation blockade in CSF3R-mutant AML$379,538
R01 · FY2022 · CA · contact PI
Role of ASXL1 in normal and abnormal granulopoiesis.$479,787
R01 · FY2021 · HL · contact PI
Mechanisms of differentiation blockade in CSF3R-mutant AML$379,538
R01 · FY2021 · CA · contact PI
Pathogenic Mechanisms of CSF3R Mutations in Leukemia$239,586
R00 · FY2018 · CA · contact PI
Pathogenic Mechanisms of CSF3R Mutations in Leukemia$244,361
R00 · FY2017 · CA · contact PI
Pathogenic Mechanisms of CSF3R Mutations in Leukemia$248,998
R00 · FY2016 · CA · contact PI
Pathogenic Mechanisms of CSF3R Mutations in Leukemia$80,618
K99 · FY2015 · CA · contact PI
Pathogenic Mechanisms of CSF3R Mutations in Leukemia$80,618
K99 · FY2014 · CA · contact PI